Publication date: Jul 10, 2019
CAMBRIDGE, Massachusetts, July 9, 2019 /PRNewswire/ — EIP Pharma, Inc. , a CNS-focused therapeutics company, today announced the initiation of a new Phase 2 proof-of-concept study evaluating neflamapimod as a treatment for the cognitive dysfunction associated with Huntington’s disease, a rare, genetically inherited disease that causes the nerve cells of the brain to progressively degenerate.
The primary objective of the study is to determine whether neflamapimod, a brain-penetrant, oral small molecule that inhibits the enzyme p38 alpha, can reverse the hippocampal synaptic dysfunction associated with early Huntington’s disease.
“We believe that neflamapimod has the potential to treat cognitive impairments associated with Huntington’s disease and can therefore benefit patients early in the course of their disease.
Recently, impairment in hippocampus-dependent cognitive function was defined as one of the earliest clinical manifestations of Huntington’s disease.
This Phase 2 proof-of-concept study is a double-blind, placebo-controlled, two-period, 10-week treatment, within-subject, crossover study of neflamapimod in early-stage Huntington’s disease (HD), with a washout period of eight to 12 weeks between the two treatment periods.
- Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease
- Why the absence of hope may be hurting Huntington’s disease research